you are viewing a single comment's thread.
Sales acctually started in January.I think we have a strategic struggel between Meda and Epicept, the one who affords waiting wins, so to speak.The results from the post-approval study out later this spring? One of the cards to be played. A factorial trial without M2 will be a success, I think. Sell the US market to another CO.Amiket gives Ceplene a new context, no need for a rush here (that is from Epicepts perspectiv. Patients perspectiv, hm.)